Lercanidipine calcium channel blocker with unique properties – why should it be used in everyday clinical practice? Review article
Article Sidebar
Published:
Dec 31, 2014
Keywords:
lercanidipine, lipophilicity, nephroprotection, leg oedema
Main Article Content
Abstract
Lercanidipine is vasoselective, dihydropyridine calcium chanel blocker with a proven effective hypotensive properties. It is the newest representative of the family of calcium chanel blockers, which, thanks to the lipophilic properties has slower onset and longer duration of action than many other calcium chanel blockers. Other studies suggest that lercanidipine can also protect against organ damage and reduce the progression of chronic kidney disease, which is particularly important in patients with hypertension. At the same time lercanidipine is better tolerated by patients than most of the other calcium chanel blockers.
Article Details
How to Cite
Szymański , F. M. (2014). Lercanidipine calcium channel blocker with unique properties – why should it be used in everyday clinical practice?. Medycyna Faktow (J EBM), 7(4(25), 102-108. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2346
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Bledowski P., Mossakowska M., Chudek J. et al.: Medical, psychological and socioeconomic aspects of aging in Poland: assumptions and objectives of the PolSenior project. Exp. Gerontol. 2011; 46: 1003-1009.
2. Głuszek J., Pawlaczyk K.: Działania niepożądane antagonistów wapnia. Choroby Serca i Naczyń 2006; 3: 18-31.
3. Charakterystyka produktu leczniczego Primacor [online: http://www.urpl.gov.pl/drugs/7758010].
4. Barrios V., Navarro A., Esteras A. et al.; Investigators of ELYPSE Study (Eficacia de Lercanidipino y su Perfil de Seguridad): Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press 2002; 11: 95-100.
5. Barbagallo Sangiorgi G., Putignano E., Calcara L. et al.: Efficacy and tolerability of lercanidipine vs. captopril in patients with mild to moderate hypertension in a double-blind controlled study. J. Cardiovasc. Pharmacol. 1997; 29(supl. 2): S36-39.
6. James I.G.V., Jones A., Davies P.: A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J. Hum. Hypertens. 2002; 16: 605-610.
7. Morisco C., Trimarco B.: Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a doubleblind controlled study. J. Cardiovasc. Pharmacol. 1997; 29(supl. 2): S26-30.
8. Notarbartolo A., Rengo F., Scafidi V. et al.: Long-term effects of lercanidipine on the lipoprotein and apolipoprotein profile of patients with mild-to-moderate essential hypertension. Curr. Ther. Res. 1999; 60: 228-236.
9. Epstein M.: Lercanidipine: a novel dihydropyridine calcium-channel blocker. Heart Dis. 2001; 3: 398-407.
10. Lund-Johansen P., Stranden E., Helberg S. et al.: Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J. Hypertens. 2003; 21: 1003-1010.
11. Ioulios P., Charalampos M., Efrossini T.: The spectrum of cutaneous reactions associated with calcium antagonists: A review of the literature and the possible etiopathogenic mechanisms. Dermatol. Online J. 2003; 9: 6.
12. Leonetti G.: The safety profile of antihypertensive drugs as the key factor for the achievement of blood pressure control: current experience with lercanidipine. High Blood Press 1999; 8: 92-101.
13. Fogari R., Malamani G.D., Zoppi A. et al.: Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind, randomized, parallel group study. Curr. Ther. Res. Clin. Exp. 2000; 61: 850-862.
14. Bang L.M., Chapman T.M., Goa K.L.: Lercanidipine. A Review of its Efficacy in the Management of Hypertension. Drugs 2003; 63: 2449-2472.
15. McClellan K.J., Jarvis B.: Lercanidipine: a review of its use in hypertension. Drugs 2000; 60: 1123-40.
16. Papavassiliou M.V., Vyssoulis G.P., Karpanou E.A. et al.: Side effects of antihypertensive treatment with calcium channel antagonists. Am. J. Hypertens. 2001; 14: 114A.
17. Barrios V., Escobar C., de la Figuera M. et al.: Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study. Cardiovasc. Ther. 2008; 26: 2-9.
18. Sabbatini M., Leonardi A., Testa R. et al.: Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35: 775-779.
19. Robles N.R., Romero B., de Vinuesa E.G. et al.: Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren. Fail. 2010; 32: 192-197.
20. Robles N.R., Ocon J., Gomez C.F. et al.: Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren. Fail. 2005; 27: 73-80.
21. Leonardi A., Poggesi E., Taddei L. et al.: In vitro calcium antagonist activity of lercanidipine and its enantiomers. J. Cardiovasc. Pharmacol. 1997; 29(supl. 1): S10-18.
22. Meredith P.A.: Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin. Invest. Drug. 1999; 8: 1043-1062.
23. Guarneri L., Angelico P., Ibba M. et al.: Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. Arzneimittel Forschung 1996; 46: 15-24.
24. Angelico P., Guarneri L., Leonardi A. et al.: Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J. Pharm. Pharmacol. 1999; 51: 709-714.
25. Sironi G., Colombo D., Greto L. et al.: Antihypertensive activity of lercanidipine and its enantiomers in animal models. J. Cardiovasc. Pharmacol. 1997; 29(supl. 1): S33-40.
26. Testa R., Rimoldi O., Sironi G. et al.: Hemodynamic effects and power spectral analysis of heart rate and arterial pressure variabilities induced by lercanidipine and its enantiomers in conscious dogs. J. Cardiovasc. Pharmacol. 1997; 29(supl. 1): 78-85.
27. Guarneri L., Sironi G., Angelico P. et al.: In vitro and in vivo vascular selectivity of lercanidipine and its enantiomers. J. Cardiovasc. Pharmacol. 1997; 29(supl. 1): S25-32.
28. Bianchi G., Passoni A., Griffini P.L.: Effects of a new calcium antagonist, Rec 15/2375, on cardiac contractility of conscious rabbits. Pharmacol. Res. 1989; 21: 193-200.
29. Soma M.R., Natali M., Donetti E. et al.: Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. Br. J. Pharmacol. 1998; 125: 1471-1476.
30. Corsini A., Bonfatti M., Quarato P. et al.: Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes. J. Cardiovasc. Pharmacol. 1996; 28: 687-694.
31. Harada N., Yamaguchi H., Shigematsu K. et al.: Effects of lercanidipine, a novel calcium antagonist, on stroke-prone spontaneously hypertensive rats [abstract]. SHR Congress. 1999 Aug 26-27; Sapporo.
32. Fogari R., Mugellini A., Corradi L. et al.: Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients [abstract]. J. Hypertens. 2000; 18(supl. 2): S65.
2. Głuszek J., Pawlaczyk K.: Działania niepożądane antagonistów wapnia. Choroby Serca i Naczyń 2006; 3: 18-31.
3. Charakterystyka produktu leczniczego Primacor [online: http://www.urpl.gov.pl/drugs/7758010].
4. Barrios V., Navarro A., Esteras A. et al.; Investigators of ELYPSE Study (Eficacia de Lercanidipino y su Perfil de Seguridad): Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press 2002; 11: 95-100.
5. Barbagallo Sangiorgi G., Putignano E., Calcara L. et al.: Efficacy and tolerability of lercanidipine vs. captopril in patients with mild to moderate hypertension in a double-blind controlled study. J. Cardiovasc. Pharmacol. 1997; 29(supl. 2): S36-39.
6. James I.G.V., Jones A., Davies P.: A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J. Hum. Hypertens. 2002; 16: 605-610.
7. Morisco C., Trimarco B.: Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a doubleblind controlled study. J. Cardiovasc. Pharmacol. 1997; 29(supl. 2): S26-30.
8. Notarbartolo A., Rengo F., Scafidi V. et al.: Long-term effects of lercanidipine on the lipoprotein and apolipoprotein profile of patients with mild-to-moderate essential hypertension. Curr. Ther. Res. 1999; 60: 228-236.
9. Epstein M.: Lercanidipine: a novel dihydropyridine calcium-channel blocker. Heart Dis. 2001; 3: 398-407.
10. Lund-Johansen P., Stranden E., Helberg S. et al.: Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J. Hypertens. 2003; 21: 1003-1010.
11. Ioulios P., Charalampos M., Efrossini T.: The spectrum of cutaneous reactions associated with calcium antagonists: A review of the literature and the possible etiopathogenic mechanisms. Dermatol. Online J. 2003; 9: 6.
12. Leonetti G.: The safety profile of antihypertensive drugs as the key factor for the achievement of blood pressure control: current experience with lercanidipine. High Blood Press 1999; 8: 92-101.
13. Fogari R., Malamani G.D., Zoppi A. et al.: Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind, randomized, parallel group study. Curr. Ther. Res. Clin. Exp. 2000; 61: 850-862.
14. Bang L.M., Chapman T.M., Goa K.L.: Lercanidipine. A Review of its Efficacy in the Management of Hypertension. Drugs 2003; 63: 2449-2472.
15. McClellan K.J., Jarvis B.: Lercanidipine: a review of its use in hypertension. Drugs 2000; 60: 1123-40.
16. Papavassiliou M.V., Vyssoulis G.P., Karpanou E.A. et al.: Side effects of antihypertensive treatment with calcium channel antagonists. Am. J. Hypertens. 2001; 14: 114A.
17. Barrios V., Escobar C., de la Figuera M. et al.: Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study. Cardiovasc. Ther. 2008; 26: 2-9.
18. Sabbatini M., Leonardi A., Testa R. et al.: Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35: 775-779.
19. Robles N.R., Romero B., de Vinuesa E.G. et al.: Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren. Fail. 2010; 32: 192-197.
20. Robles N.R., Ocon J., Gomez C.F. et al.: Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren. Fail. 2005; 27: 73-80.
21. Leonardi A., Poggesi E., Taddei L. et al.: In vitro calcium antagonist activity of lercanidipine and its enantiomers. J. Cardiovasc. Pharmacol. 1997; 29(supl. 1): S10-18.
22. Meredith P.A.: Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin. Invest. Drug. 1999; 8: 1043-1062.
23. Guarneri L., Angelico P., Ibba M. et al.: Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. Arzneimittel Forschung 1996; 46: 15-24.
24. Angelico P., Guarneri L., Leonardi A. et al.: Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J. Pharm. Pharmacol. 1999; 51: 709-714.
25. Sironi G., Colombo D., Greto L. et al.: Antihypertensive activity of lercanidipine and its enantiomers in animal models. J. Cardiovasc. Pharmacol. 1997; 29(supl. 1): S33-40.
26. Testa R., Rimoldi O., Sironi G. et al.: Hemodynamic effects and power spectral analysis of heart rate and arterial pressure variabilities induced by lercanidipine and its enantiomers in conscious dogs. J. Cardiovasc. Pharmacol. 1997; 29(supl. 1): 78-85.
27. Guarneri L., Sironi G., Angelico P. et al.: In vitro and in vivo vascular selectivity of lercanidipine and its enantiomers. J. Cardiovasc. Pharmacol. 1997; 29(supl. 1): S25-32.
28. Bianchi G., Passoni A., Griffini P.L.: Effects of a new calcium antagonist, Rec 15/2375, on cardiac contractility of conscious rabbits. Pharmacol. Res. 1989; 21: 193-200.
29. Soma M.R., Natali M., Donetti E. et al.: Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. Br. J. Pharmacol. 1998; 125: 1471-1476.
30. Corsini A., Bonfatti M., Quarato P. et al.: Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes. J. Cardiovasc. Pharmacol. 1996; 28: 687-694.
31. Harada N., Yamaguchi H., Shigematsu K. et al.: Effects of lercanidipine, a novel calcium antagonist, on stroke-prone spontaneously hypertensive rats [abstract]. SHR Congress. 1999 Aug 26-27; Sapporo.
32. Fogari R., Mugellini A., Corradi L. et al.: Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients [abstract]. J. Hypertens. 2000; 18(supl. 2): S65.